Merlin is a 100x-or-bankrupt opportunity, too binary to invest in personally despite liking Merlin and Matt. Shield AI and Anduril are focused on defense right now, but it makes sense for them to go after the commercial sector eventually with proven tech, and more competitors are targeting cargo. The stock should rebound once high-beta names come back into favor. x.com 

Merlin Labs common stock is in a death spiral toward zero because preferred holders and shorts hold the upper hand. Equity raises have no limit and the preferred ranks senior to the common, so fundamental analysis does not matter. @ShawarmaCapital, a former bull, attributes the fall from $17 to $1.81 to a roughly 44M-share unlock on a thin float, a Series A Preferred conversion reset on October 15 already headed for its $5 floor, and an unwinding short squeeze. x.com  x.com 

Merlin's finished Critical Design Review for its C-130J autonomy program with US Special Operations Command removes a big chunk of technical risk. It shows Merlin Pilot AI meets the performance, safety and airworthiness standards for one of the military's key transport aircraft, and the program moves to integration and flight tests. A $100 million-plus IDIQ ceiling and commercial runway in cargo and pilot shortages make it asymmetric, and high short interest adds explosive potential. x.com 

Merlin was always highly speculative: buying a stock at 125x sales means accepting it could fall to 30x without any solid reason why it shouldn't. Its price spike came when it was being pitched like crazy on X. x.com  x.com 

Lockheed Martin, now down for the year, is a buy for the long-term portfolio because defense is always needed. x.com 

Merlin trades at 5.6x FY27 revenue versus about 13x for Anduril in the same autonomous defense category, a public-market discount, and completing a USSOCOM design review clears its first hard gate. Per @mkfilko, its certified, aircraft-agnostic autonomy software replaces pilot labor and has flown on more than seven airframe types, including KC-135 tankers and C-130J transports, and the stock could double and still sit at Anduril's multiple. Production contract timing is the open question. x.com 

Lockheed Martin is cheap against its earnings, trading at 22x trailing and 18x next year's, versus the 24x aerospace and defense suppliers usually get. At 24x next year's $32.72 EPS, give or take 12%, fair value runs $690.97 to $879.42, so the stock sits 15% below where fair value starts. This is a valuation read on reported earnings and estimates only, not fundamental work. x.com 

Lockheed Martin is the straightforward defense buy, with a 3.2x book-to-bill. The stock fell last quarter because capex rose to meet very high demand, a dumb reaction. @kaizen_cap adds that money from awarded contracts flows over multiple years, so peak awards and revenue recognition may come in 2027-2028 even with a flat budget. x.com  x.com 

Merlin's deal with Israel Aerospace Industries adds credibility and a distribution path, though not revenue, and kills the argument that there is no large-aircraft market, per @ShawarmaCapital. IAI did $7.4B of revenue last year, holds a roughly $29B backlog and leads passenger-to-freighter conversions, owning the only approved 777 widebody conversion in service. There is certainly a future market for large civil aircraft. x.com 

Kraken Robotics is not yet a buy despite falling almost 60% from its high. It should first report combined results with Covelya that preserve a credible growth and margin path, and the stock should form a base; the defence factor remains deeply out of favor. @DeepSailCapital argues it is near a bottom, expecting CAD 0.20 of 2028 EPS, mid-20s to 30s revenue growth and product ramps with Anduril. x.com  x.com